---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-23-000020"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T04:00:51.702736+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio cuts US headcount to ~15, consolidates operations to UK, expects cash runway beyond 2026

## Summary
- Will extend reduction-in-force to ~15 US employees; transition ITIL-306 manufacturing and trial to Manchester, UK.
- Estimates total restructuring costs up to $3.0M, excluding potential facility sale charges.
- Evaluating potential sale/sublease of Tarzana, CA manufacturing site to further extend cash runway.
- Expects cash runway beyond 2026; initial ITIL-306 clinical data still expected in 2023.

## SEC filing metadata
- accession: 0001789769-23-000020
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000020/0001789769-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000020/til-20230130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-23-000020
- JSON: https://secwatch.observer/filing/0001789769-23-000020.json
- Plain text: https://secwatch.observer/filing/0001789769-23-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.